Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22100089 | 0.88 | OPRM1 (0.43) | OPRM1OPRD1OPRK1NPC1ALDH1A1 | |
| SCHEMBL22100058 | 0.75 | OPRM1 (0.43) | OPRM1OPRD1OPRK1NPC1ALDH1A1 | |
| SCHEMBL24746973 | 0.75 | ALDH1A1 (0.47) | NPC1ALDH1A1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL25857137 | 0.73 | OPRM1 (0.41) | OPRM1OPRD1OPRK1NPC1ALDH1A1 | |
| SCHEMBL19388140 | 0.73 | OPRM1 (0.41) | OPRM1OPRD1OPRK1NPC1ALDH1A1 | |
| SCHEMBL25857161 | 0.70 | KDM4E (0.32) | ALDH1A1AKT1 | |
| SCHEMBL22863834 | 0.70 | OPRM1 (0.47) | OPRM1OPRD1OPRK1NPC1ALDH1A1 | |
| SCHEMBL18666981 | 0.70 | OPRM1 (0.47) | OPRM1OPRD1OPRK1NPC1ALDH1A1 | |
| SCHEMBL20125232 | 0.70 | MAOA (0.36) | ALDH1A1 | |
| SCHEMBL26769418 | 0.70 | MAOA (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10688189-B1 | Modulated guanidine-containing polymers or nanoparticles | THE FLORIDA INTERNATIONAL BOARD OF TRUSTEES (US) | 2020-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10688189-B1 | Modulated guanidine-containing polymers or nanoparticles | RNMT, NAT10, GMPS | OPRM1 478/4885OPRD1 2498/4885OPRK1 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.